文献速递造血干细胞移植与细胞治疗

西格列汀预防替代供者移植急性GVHD的III期随机试验

Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial.
PubMed 文献 · J Clin Oncol · 2026-10-06

这项前瞻性多中心开放标签随机试验纳入190例接受清髓性替代供者移植的血液肿瘤患者,评估在ATG基础预防方案中加入西格列汀能否降低急性GVHD发生率。结果显示西格列汀组第+100天II-IV级aGVHD累积发生率显著降低(14.7% vs 31.6%,sHR=0.41,P=.005),但长期GRFS、总生存及无复发生存无显著获益。

要点

  • 西格列汀联合ATG预防显著降低第+100天II-IV级aGVHD发生率(14.7% vs 31.6%)。
  • III-IV级及肠道aGVHD发生率亦降低,第+180天GRFS更优。
  • 2年慢性GVHD、非复发死亡、复发/生存及病毒感染无组间差异。

核心结论

  • 在ATG基础预防方案中加入西格列汀可显著降低替代供者移植后II-IV级aGVHD发生率。

研究设计与样本

  • 前瞻性、多中心、开放标签、随机III期试验,纳入190例18-60岁接受清髓性单倍体或不相关供者移植的血液肿瘤患者。
  • 按1:1随机分配至ATG基础预防方案联合或不联合西格列汀(600 mg口服,每12小时一次,第-1天至+14天)。

主要发现

  • 西格列汀组第+100天II-IV级aGVHD累积发生率为14.7%,对照组为31.6%(sHR=0.41,P=.005)。
  • III-IV级aGVHD发生率为6.3% vs 18.9%(sHR=0.30,P=.010),肠道aGVHD为12.6% vs 29.5%(P=.004)。
  • 第+180天GRFS为86.3% vs 72.6%(HR=0.44,P=.016)。
  • 2年慢性GVHD、非复发死亡、无复发生存/总生存及巨细胞病毒/EB病毒再激活无组间差异,不良事件谱相似。

关键数值与推荐

  • 西格列汀用法:600 mg口服,每12小时一次,第-1天至+14天。
  • 主要终点为第+100天II-IV级aGVHD累积发生率。

临床怎么用

  • 对于接受ATG基础预防的替代供者清髓性移植患者,可考虑加用西格列汀以降低早期II-IV级aGVHD风险。
  • 需注意严重及肠道aGVHD降低和GRFS改善为探索性观察,长期生存获益未证实。

局限性

  • 开放标签设计可能引入偏倚。
  • 随访时间有限(中位29.8个月),长期结局需进一步验证。
  • 严重及肠道aGVHD和GRFS改善为探索性终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This trial evaluated whether the addition of sitagliptin to antithymocyte globulin (ATG)-based prophylaxis reduces the incidence of acute graft-versus-host disease (aGVHD) after alternative donor hematopoietic stem-cell transplantation. METHODS: This prospective, multicenter, open-label, randomized trial enrolled patients age 18-60 years with hematologic malignancies who received myeloablative conditioning haploidentical or unrelated donor transplantation. Participants were randomly assigned in a 1:1 ratio to ATG-based prophylaxis (ATG + calcineurin inhibitor + methotrexate + mycophenolate mofetil) with or without sitagliptin (600 mg orally once every 12 hours, days -1 to +14). The primary end point was the cumulative incidence of grade Ⅱ-Ⅳ aGVHD by day +100. RESULTS: From December 22, 2021, to June 16, 2023, 190 of the 251 screened patients were enrolled, with a median follow-up of 29.8 (0.7-41.3) months. The sitagliptin group had a significantly lower incidence of grade Ⅱ-Ⅳ aGVHD on day +100 (14.7% v 31.6%; subdistribution hazard ratio [sHR] = 0.41; P = .005). Reduced grade Ⅲ-Ⅳ (6.3% v 18.9%; sHR = 0.30; P = .010) and intestinal aGVHD (12.6% v 29.5%; P = .004) and superior day +180 GVHD-free, relapse-free survival (GRFS; 86.3% v 72.6%; HR = 0.44; P = .016) were also observed. No between-group disparities were detected in 2-year chronic GVHD, nonrelapse mortality, relapse-free/overall survival, or cytomegalovirus/Epstein-Barr virus reactivation; the adverse event profiles were similar. CONCLUSION: In this randomized trial, adjunct sitagliptin to ATG-containing prophylaxis significantly reduced the incidence of grade Ⅱ-Ⅳ aGVHD. Reductions in severe and intestinal aGVHD, as well as improved day +180 GRFS, were exploratory observations; no significant benefits were detected for long-term GRFS, overall survival, or RFS, and treatment did not alter the engraftment, relapse, or infection risk.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Qiao M, Zhou B, Chen Y, et al. Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial. J Clin Oncol. 2026. PMID: 42837636. doi:10.1200/JCO-26-00670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。